Ptc Therapeutics (PTCT) Gross Profit (2016 - 2026)

Ptc Therapeutics' Gross Profit history runs 11 years deep, the most recent figure standing at $244.5 million for Q1 2026.

• On a quarterly basis, Gross Profit fell 78.98% year-over-year to $244.5 million in Q1 2026; TTM through Mar 2026 was $764.9 million, a 50.02% decrease from a year earlier, with the FY2025 full-year figure at $1.7 billion, up 124.67% from the prior year.
• Gross Profit grew to $244.5 million in Q1 2026 per PTCT's latest filing, from $157.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $1.2 billion in Q1 2025 and bottomed at -$15.5 million in Q2 2024.
• The 5-year median for Gross Profit is $195.2 million (2025), against an average of $236.3 million.
• Across the five-year window, Gross Profit sank 107.72% in 2024 and soared 1178.48% in 2025, its largest moves.
• Year by year, Gross Profit stood at $156.5 million in 2022, then jumped by 77.57% to $277.9 million in 2023, then declined by 29.16% to $196.9 million in 2024, then declined by 19.89% to $157.7 million in 2025, then soared by 55.03% to $244.5 million in 2026.
• Per Business Quant, the three latest PTCT Gross Profit figures stand at $244.5 million (Q1 2026), $157.7 million (Q4 2025), and $195.2 million (Q3 2025).